At a glance
ClinicalIndex Comparison Record- ✓Female gender
- ✓Age ≥18 years
- ✓Stage 1: Invasive ductal carcinoma or DCIS proven by core needle biopsy
- ✓Stage 2: Invasive carcinoma proven by core needle biopsy
- ✕Distant metastases
- ✕Currently undergoing neoadjuvant therapy
- ✕Positive preoperative axillary assessment (Stage 1)
- ✕Positive preoperative axillary assessment (Stage 2: PET mSUV≥0.27)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sentinel Node Biopsy Vs Observation After Axillary PET Examination
In Brief
A clinical study evaluating SLNB is spared for Breast Cancer. Currently recruiting, targeting 1,528 participants across 1 site.
Detailed Summary
Several researches have proved that avoiding axillary surgery does not worsen the outcome of breast cancer patients with relatively low risk. Based on the routine axillary imaging evaluation (ultrasound and MR etc.) and latest dedicate lymph node PET (LymphPET), axillary nodal burden can be identified before operation. Therefore this prospective study are designed to evaluate the negative predictive value of LymphPET and to verify whether sentinel lymph node biopsy can be spared in patients with negative preoperative axillary assessment.
Study Details
Timeline
Interventions
SLNB is spared in patients with negative preoperative axillary assessment(including LymphPET and other imaging examinations)